MR 1268, a benzmorphan derivative with marked morphine-like properties and weaker antagonist properties was administered to six healthy male volunteers who each received MR 1268 2.5,5,10 and 20 mg i.v. in random order. There were no significant changes in the cardiovascular indices measured. However, significant and dose-related decreases in expired minute volume were observed. With 20 mg, consistent increases in PB COI coincided With maximum decrease in ventilation, indicating some degree of alveolar hypoventilation. Drowsiness was dose-related but of short duration and only significant with 20 mg. Pupillary size and reaction remained unaffected.
MR 1268 [3-(2-methyl-3-furylmethyl)-l ,2,3,4,5,6-hexahydro-6, ll-dimethyl-2, 6-methano-3-benzazocin-8-ol-methansulphonate] is a benzmorphan derivative ( fig. 1 ) with marked morphine-like properties and Weaker antagonist properties. It has been synthesized by Boehringer Ingelheim in an attempt to produce an acceptable, non-habit-forming analgesic with a satisfactory duration of action. Experiments on mice (J. H. Shelley personal communication) have shown that, when given parenterally, the drug has 1-2 times the potency of pentazocine and between one-third and the same as that of morphine. Its duration of action is intermediate between the two compounds. The antagonist effect was demonstrated in mice by injecting morphine and MR 1268 simultaneously into two different sites and noting a less marked analgesic effect compared with animals receiving morphine alone. Like pentazocine, it does not produce a nalorphine-like intensifying effect on withdrawal symptoms. It would appear that MR 1268 has the pentazocine-like advantages over morphine in being a potent analgesic with little dependence-producing properties.
Preliminary studies of the analgesic action of MR 1268, carried out in West Germany in 1978, showed that 2.5-10 mg s:c. gave relief of pain following abdominal operations with minimal side-effects. Further studies with 15-30mg i.m. suggested that MR 1268 was approximately equipotent with pentazocine. Subjective sideeffects were trivial and there was no evidence of the psychotomimetic problems which decrease the acceptability of pentazocine (Beaver et al., 1966; Hamilton et al., 1967) .
The present study was designed to assess the cardiovascular and respiratory side-effects of a wide range of doses of MR 1268 i.v. to volunteers, including "no measureable effect" at the lower (2.5 mg) and significant respiratory depression at the upper (20mg) end. These volunteer studies enabled the effects of the drug to be evaluated in the absence of depressant anaesthetic agents and permitted assessment of subjective tolerance. The i.v. route ensured rapid and predictable uptake and accentuated the occurrence of side-effects.
SUBJECTS AND METHODS
Six volunteer anaesthetists were studied. Each was given a brochure summarizing the action of the drug and the potential hazards of the investigation. The study was approved by the local ethics committee.
The ages of the subjects ranged from 26 to 47 yr and their weights from 60 to 75 kg. Following overnight starvation they rested on a tilting couch for at least 30min before the study commenced. An i.v. infusion was started and as MR 1268 was injected some distance from the site of venepunctiire and out of the subject's view, they did not know the precise tnoment of administration. Each received MR 1268 2.5, 5, 10 and 20 mg. Apart from the initial dose of 2.5 mg, these were given in random order in a single-blind fashion, the subjects themselves being unaware of tlie dose they were receiving. The time interval between the studies in a particular volunteer was not less than seven days.
The plan of the study is shown diagramatically in figure 2, the following indices being recorded where shown:
The cannula also provided an opportunity to record arterial pressure continuously by connecting it to a pen recorder (Washington 400 MD/2) via a light weight transducer (Gaeltec Luer). Measurements of arterial pressure were made in the recumbent and in the reverse Trendelenberg position (40° head-up tilt) to detect the possible occurrence of postural hypotension after the administration of MR 1268t Three control readings were taken at. 10-rriin intervals during the period before the administration of the drug and mean values calculated.
Precordial e.c.g. electrodes were applied and a continuous record obtained through the study. Heart rate was calculated from the e.c.g. tracing. 
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Cardiovascular measurements. Systolic and diastolic arterial pressures were measured with an oscillotonometer, the same apparatus being used in all the subjects and all observations were made by one observer. With the 20-mg dose, percutaneous radial artery cannulation was performed under local anaesthesia before commencing the study to measure the changes in P^Q O , and rate and minute volume were obtained throughout the 10-min period, only the results obtained during the final minute of each period were analysed ( fig. 2) .
When MR 1268 20 mg was given, 1 ml of arterial blood was withdrawn in a previously heparinized syringe at the intervals shown in figure 2 and analysed immediately for Pa COi and Ps^^ using an IL400 blood-gas analyser (Instrumentation Laboratories Ltd).
Soporific effect. The degree of drowsiness was assessed periodically and graded by the observer as: 0 = fully awake; 1 = slight drowsiness; 2 = moderate drowsiness; 3 = extremely drowsy but easily roused; 4 = asleep.
Peg-board performance test. The time taken to transfer six pegs from one side of the board to the other was noted (Carson, 1975) before the administration of the drug, the mean of three tests being taken as the control. The subjects attempted the test at 5, 15 and 30min after the injection of MR 1268 and at 30-min intervals until the "control" result was attained again.
Pupillary size and reaction. A National Heart Hospital pupil gauge (MIE) was held in front of the eye and the size of the pupil was matched against the appropriate perforation of a known diameter on the gauge. These measurements were made under standard lighting conditions and again when a beam of light was shone on the eye.
Subjective effects. The occurrence of the following side-effects was classified in a standardized interview: pain on injection, dry mouth, dizziness, euphoria, hallucinations, dreams or any other subjective effects. The occurrence of sweating during the study was recorded.
In this investigation each subject acted as his own control and the paired data were analysed by the Student's t test, average and standard error of the mean being given in the tables.
RESULTS
Cardiovascular measurements. The changes in mean arterial pressure were small and not statistically significant (table I) . There was no evidence of postural hypotension with a 40° headup tilt in any of the subjects.
A slight but statistically significant decrease in mean heart rate was observed with all four doses of MR 1268 (table II) (P<0.05 to <0.001). The maximum decrease occurred 30 min following the 10-mg dose.
Respiratory measurements. Respiratory frequency was practically unaltered after all four doses of MR 1268 (table III) . Small changes in either direction were not significant.
An increase in average minute volume occurred after MR 1268 2.5 mg, but consistent decreases were noted following the 5-, 10-and 20-mg doses P&co 2 . Each value shown against individual subjects in table V represents an average of two or three measurements. Following MR 1268 20 mg, five of six subjects studied showed an increase of greater than 0.7 kPa at 5 min (P< 0.001). At 15 min, Pa^ remained increased significantly (P< 0.001). At 15 min, Pa COl remained increased significantly (P < 0.001) the average increase being 0.5 kPa above baseline; at 30 min the average increase was 0.4kPa (P<0.001). At 60min, however, only one subject (No. 2) showed a sustained increase of Pa COi greater than 0.7 kPa, while the others showed negligible increases which were not significant. For technical reasons it was possible to report Pa^ changes in only five subjects (table VI) . Individual findings given in table VI are based on an average of two to three measurements. The average resting Pa Oj of 12.5kPa (range 12.1-12.9) was well within the normal physiological limits. Following MR 1268 20 mg there was a variable decrease; at 5 min the average decrease of 1.1 kPa (range 0.1-2.4) was significant (P< 0.025). More consistent decreases were seen at 10 min (average decrease = 1.3 kPa (range 1.2-1.6) (P< 0.001)).
Soporific effect. Subjects appeared to be unaffected by MR 1268 2.5 and 5 mg ( fig. 4) . With the 10-mg dose, five out of six subjects were slightly drowsy (at 5 and 15 min), the other being unaffected. All had recovered completely by 60 min. Following MR 1268 20 mg, one subject was moderately drowsy and the rest only slightly drowsy 5 min after injection. By 30 min, the soporific effects had begun to wane, although slight drowsiness persisted for up to 90 min in three of the subjects. All had recovered fully by 120 min. The most significant observation was that subjects seemed to emerge from the varying periods of sedation rather abruptly, exhibiting a clear-cut end point. The ability to undertake the peg-board performance test remained unchanged after MR 1268 2.5 mg. Following 5, 10 and 20 mg the time taken to return to pre-injection performance increased proportionately ( fig. 5 ). Pupillary size and reaction to light. These remained unchanged with all doses of MR 1268. The average pupillary diameter was 5 mm under standard room light, which decreased to 3 mm when a beam of light was shone towards the eyes. The reaction remained brisk and unaffected by the drug.
Subjective effects. Three of the six subjects studied reported a sensation of generalized warmth spreading all over the body within a few seconds of the injection. A "pleasant feeling" lasting for about 10 min followed the 10-and 20-mg doses of MR 1268 in two subjects. Apart from these, no other subjective effects were noticed.
DISCUSSION
The effect of a potent analgesic in a group of healthy, pain free, human volunteers may not truly represent the response from a group of patients in severe pain. Nevertheless, such studies do have a place in the initial investigation of a drug as they provide valuable information unobtainable from animal experiments and they demonstrate the general trends in the likely pharmacological response in patients.
There were no noteworthy changes in cardiovascular variables following MR 1268. The slight decrease in heart rate bore no relationship to the dose of the drug and was most probably a result of physical and mental relaxation.
The lack of significant changes in respiratory rate is notable, in view of the fact that this is often taken as an index of respiratory depression. Following MR 1268 2.5 mg, small increases in minute volume were noticed. This response was totally different from the consistent decreases subsequently seen with higher doses and it could be a result of conscious overbreathing on first exposure to the apparatus. It supports the original supposition that 2.5 mg is a "no-effect dose", at least in terms of respiratory depression, and the inclusion of this low dose was the reason for omission of a placebo in the study. Following MR 1268 5, 10 and 20 mg a much clearer trend emerged and decreases in minute volume seen were not only significant but also dose-related.
IL is difficult to draw any firm conclusions from the changes in respiratory indices, particularly since a decrease in ventilation alone does not necessarily indicate respiratory depression. Jennet, Barker and Forrest (1968) have shown that potent analgesics such as morphine, phenoperidine and pentazocine reduce the basal metabolic rate with inevitable alterations in the respiratory pattern. Also, Bellville and his colleagues (1959) have observed that natural sleep per se can affect the respiratory indices and, when this effect cannot be separated from the true drug effect, it must be taken into account in assessing the extent of respiratory depression.
It is claimed that an increase in Pco 2 in subjects breathing room air, is a reliable index of "true" respiratory depression (Jennett, Barker and Forrest, 1968) . In the present study, following MR 1268 20 mg, all subjects with one exception showed an increase in Paico, of the order of 0.7 kPa or more, within 5min of the i.v. injection. Although these increases were not large, the consistency with which they occurred is significant, and they coincided with the maximum decreases in ventilation. Pa^, remained increased significantly for up to 30min. Changes in POQ, were small and inconsistent. Although PZQ^ is expected to decrease as P&c O , increases, this can be altered by factors other than those causing respiratory depression and is not a useful criterion.
Like other opiates, MR 1268 would seem to produce dose-related drowsiness, but this was of short duration and only significant with 20 mg. Although the peg-board test may not be an ideal method of assessing recovery, it is simple to use and reproducible in its findings (Vickers, 1965; Carson, 1975) . Apart from 2.5 mg, which had no effect, all other doses of MR 1268 (5,10 and 20 mg) decreased the subjects' ability to undertake the peg-board performance test. As a result, the time taken to return to pre-injection performance increased with increasing dose.
Slight meiosis was reported following MR 1268 20-30mg s.c. in a previous study involving three healthy volunteers; reaction to light remained uninhibited (J. H. Shelley, personal communication).
Sweating was the commonest side-effect reported to have occurred with a dose as low as 5 mg in both volunteers and patients during the studies undertaken in West Germany. After 20-30 mg s.c. mild vertigo and poor concentration followed by apathy and nightmares were reported in a small number of subjects. None of these sideeffects was experienced by any of the subjects in the present study. El MR 1268 es un dcrivado befizomorfinico con propiedades marcadamente similares a las de la mornna y con propiedades antergicas mas debiles. Este analgesico se administro a seis hombres sanos y voluntarios, recibiendo cada uno de" ellos 2,5, 5, 10 y 20 mg de MR 1268 al azaf. Istb se presentaron cambios significativos en los indices cardiovasculares medidos. Sin embargo, se observaron disminucioncs significativas y relacionadas con la dosis en el volumen diminuto espirado. Con 20mg se presentaron incrementos consistentes en Pa^o-'ĉ uales coincidieron con la disminucion maxima de la ventilacion, indicando asi ciefto grado de hipoventilacion alveolar. La somnolencia vino en fuhcion de la dosis pero fue de corta duracion y solo fue significativa con 20 mg. El tamafio y la reaccion de las pupilas no quedo afectado.
